ArticleMolecular cancer research : MCR2020
Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Proteome-wide Ubiquitinome Profiling Reveals Substrate-specific Dynamics Within the USP7 Network.Molecular & cellular proteomics : MCP · 2026Article
- Genomic Catastrophe Defines the Evolutionary Trajectory of Adrenocortical Carcinoma.Endocrine pathology · 2026Article
- Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.Nature communications · 2026Article
- Genomic Characterization of High-Grade Serous Ovarian Carcinoma Reveals Distinct Somatic Features in Black Individuals.Cancer research · 2025Article
- Transcriptional regulation by MYC: an emerging new model.Oncogene · 2025Review
- CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD.Blood advances · 2024Article
- In vivo CRISPR screens identifyProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.Leukemia · 2024Article
- Transcriptome Analysis Reveals Distinct Patterns Between the Invasive and Noninvasive Pituitary Neuroendocrine Tumors.Journal of the Endocrine Society · 2024Article
- GINS2 promotes the progression of human HNSCC by altering RRM2 expression.Cancer biomarkers : section A of Disease markers · 2024Article
- Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models.Blood advances · 2023Article
- In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.Blood cancer discovery · 2023Article
- Genomic Characterization of Prostatic Basal Cell Carcinoma.The American journal of pathology · 2023Article
- USP7 regulates the ncPRC1 Polycomb axis to stimulate genomic H2AK119ub1 deposition uncoupled from H3K27me3.Science advances · 2022Article
- SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis.Communications biology · 2022Article
- Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis.Life science alliance · 2022Article
- CircMGA Depresses Myoblast Proliferation and Promotes Myotube Formation through miR-144-5p/FAP Signal.Animals : an open access journal from MDPI · 2022Article
- Review
- Tracing the cis-regulatory changes underlying the endometrial control of placental invasion.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Paula Llabata *Cancer Epigenetics and Biology Program-PEBC (IDIBELL), Barcelona, Spain.ORCID 0000-0001-7733-6475
Yoichiro Mitsuishi *Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Peter S ChoiDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Diana CaiDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Joshua M FrancisDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Manuel Torres-DizCancer Epigenetics and Biology Program-PEBC (IDIBELL), Barcelona, Spain.ORCID 0000-0002-5487-8113
Namrata D UdeshiCancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Lior GolombDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Zhong WuDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Jin ZhouDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Tanya SvinkinaCancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Estrella Aguilera-JimenezDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-4160-2855
Yanli LiuDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Steven A CarrCancer Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Montse Sanchez-CespedesCancer Epigenetics and Biology Program-PEBC (IDIBELL), Barcelona, Spain.
Matthew MeyersonDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Xiaoyang.Zhang@hci.utah.edu Matthew_Meyerson@dfci.harvard.edu.
Xiaoyang ZhangDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Xiaoyang.Zhang@hci.utah.edu Matthew_Meyerson@dfci.harvard.edu.
Broad Institute · USHuntsman Cancer Institute · USInstitut d'Investigació Biomédica de Bellvitge · ES
Funding
NKX2-1 Enhancer Amplification and Lineage Addiction in Lung AdenocarcinomaR35CA197568 · NCI · DANA-FARBER CANCER INST · PI Matthew L. Meyerson · 2015 to 2026
$12.4MMICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALSU01CA214125 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ANURAG, MEENAKSHI, CARR, STEVEN A · 2017 to 2021
$7.0MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA210986 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, GILLETTE, MICHAEL A · 2016 to 2020
$6.4MNCI NIH HHS R35 CA197568NCI NIH HHS U01 CA214125NCI NIH HHS U24 CA210986
Abstract
Genomic analysis of lung adenocarcinomas has revealed that the
Indexed as
A549 CellsAdenocarcinoma of LungBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBasic Helix-Loop-Helix ProteinsCell Line, TumorCell ProliferationHEK293 CellsHumansLung NeoplasmsMutationProto-Oncogene Proteins c-mycBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBasic Helix-Loop-Helix ProteinsMAX protein, humanMGA protein, humanMYC protein, humanProto-Oncogene Proteins c-myc
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.